ENGLEWOOD, Colo., Dec. 27,
2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc.
(NYSE American: AMPE) (the "Company") today announced that it has
received notification from The NYSE American LLC ("NYSE American")
stating that the Company has regained compliance with the NYSE
American's continued listing standards. Specifically, the Company
has resolved the continued listing deficiency with respect to its
low selling price as described in Section 1003(f)(v) of the NYSE
American Company Guide.
In the notification, the NYSE American informed the Company that
as of December 27, 2022, the below
compliance (".BS") indicator will no longer be disseminated and the
Company has been removed from the NYSE American noncompliant
issuers on the NYSE American's website.
About Ampio Pharmaceuticals, Inc.
Ampio
Pharmaceuticals, Inc. is a pre-revenue stage biopharmaceutical
company that is engaged with the early development of AR-300, a
synthetic pre-clinical stage development asset which has been
designed to leverage the key attributes of Ampion. The Company is
currently conducting preclinical studies on AR-300 and engaged in a
strategic alternatives process that could include outbound
strategic in-licensing / acquisition efforts with a key focus on
late-stage development assets / programs which would strengthen its
existing pipeline.
For more information, contact:
Ampio Pharmaceuticals, Inc.
Michael Martino
Chief Executive Officer
mmartino@ampiopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-regains-compliance-with-nyse-american-continued-listing-standards-301710404.html
SOURCE Ampio Pharmaceuticals, Inc.